Can higher doses and steroids beat TB in HIV patients?
NCT ID NCT04738812
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a stronger tuberculosis (TB) treatment could save more lives in people with HIV and very weak immune systems. Over 1,300 hospitalized patients received either the standard TB drugs or an intensified version with higher doses of two key medicines, plus a steroid and a deworming pill. The goal was to see if the stronger regimen reduced deaths over 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
higher doses of rifampicin and isoniazid, plus prednisone and albendazole
What this could lead to
If successful, this could lead to a more effective TB treatment for people with advanced HIV, potentially reducing deaths.
What could go wrong
The trial is completed but results are not yet widely confirmed. Higher drug doses may increase side effects, and the approach may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ignace Deen Hospital
Conakry, Guinea
-
Jamot Hospital
Yaoundé, Cameroon
-
MACHAVA Hospital
Maputo, Mozambique
-
Mbarara Regional Referral hospital
Mbarara, Uganda
-
National Center for HIV/AIDS, Dermatology and STD (NCHADS)
Phnom Penh, Cambodia
-
University Teaching Hospital
Lusaka, Zambia